Compare JBI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | ZVRA |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.2M | 562.2M |
| IPO Year | 2021 | 2015 |
| Metric | JBI | ZVRA |
|---|---|---|
| Price | $5.02 | $12.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.17 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.8M | 880.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | 0.08 | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $9.36 | $37.27 |
| Revenue Next Year | $3.16 | $53.42 |
| P/E Ratio | $61.00 | ★ $16.62 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $4.26 | $7.16 |
| 52 Week High | $10.80 | $15.04 |
| Indicator | JBI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 60.07 |
| Support Level | $4.88 | $12.18 |
| Resistance Level | $5.60 | $14.27 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 56.78 | 91.91 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. It provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.